Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00157105
Status:
COMPLETED
Last Update Posted:
2021-08-24
First Post:
2005-09-08
Brief Title:
Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII rAHF-PFM in Hemophilia A Patients Undergoing Surgery
Sponsor:
Baxalta now part of Shire
Organization:
Takeda
Study Overview
Official Title:
Recombinant Antihemophilic Factor rAHF PFM Manufactured and Formulated Without Added Human or Animal Proteins Evaluation of Safety and Efficacy in Hemophilia A Patients Undergoing Surgical or Invasive Procedures
Status:
COMPLETED
Status Verified Date:
2021-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of hemophilia A patients undergoing surgery
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None